
Summit Therapeutics (SMMT) Stock Forecast & Price Target
Summit Therapeutics (SMMT) Analyst Ratings
Bulls say
Summit Therapeutics Inc. is positioning itself favorably in the biopharmaceutical sector, particularly with its CDI product candidate, ridinilazole, which has demonstrated a significant response rate among patients in the ongoing HARMONi trial, with 65% showing a PFS benefit. The anticipated positive results from ongoing Phase 3 trials, specifically for its NSCLC product, ivonescimab, are supported by an increased probability of success, which could lead to substantial market traction given the potential for peak annual sales surpassing $25 billion, akin to leading competitors. Furthermore, the company's projections for a meaningful improvement in overall survival (OS) metrics speak to its strong clinical pipeline and potential for long-term revenue growth in the highly competitive oncology market.
Bears say
Summit Therapeutics's stock faces significant challenges stemming from a low probability of success for its product candidate, Ivo, which is currently assessed at only 20% due to concerns about its clinical efficacy and potential safety signals emerging in Phase 3 studies. Additionally, a lack of differentiated clinical data and competition from newly approved drugs may severely hinder the sales potential of Summit's products, adversely impacting revenue forecasts. The company also confronts regulatory risks, clinical trial failures, and potential dilution, all of which contribute to a grim financial outlook and amplify investor uncertainty.
This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares